{"title":"业界对亚甲二氧基甲基苯丙胺试验中的掩蔽问题表示担忧","authors":"Alison Knopf","doi":"10.1002/adaw.34448","DOIUrl":null,"url":null,"abstract":"<p>Not for the first time, experts have expressed concern about whether randomized controlled trials (RCTs) can be conducted with psychedelics. A placebo for a drug with such a powerful effect would be difficult to create. But placebos are needed to prove that a medication works because it works, not because the patient thinks it will (the so-called “placebo effect”). To avoid the placebo effect misguiding results, participants are “blinded” as to whether they are taking the placebo or the study drug. (In “double-blind” studies, the researchers don't know, either.)</p>","PeriodicalId":100073,"journal":{"name":"Alcoholism & Drug Abuse Weekly","volume":"37 11","pages":"4-5"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Industry considers concerns about masking in MDMA trials\",\"authors\":\"Alison Knopf\",\"doi\":\"10.1002/adaw.34448\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Not for the first time, experts have expressed concern about whether randomized controlled trials (RCTs) can be conducted with psychedelics. A placebo for a drug with such a powerful effect would be difficult to create. But placebos are needed to prove that a medication works because it works, not because the patient thinks it will (the so-called “placebo effect”). To avoid the placebo effect misguiding results, participants are “blinded” as to whether they are taking the placebo or the study drug. (In “double-blind” studies, the researchers don't know, either.)</p>\",\"PeriodicalId\":100073,\"journal\":{\"name\":\"Alcoholism & Drug Abuse Weekly\",\"volume\":\"37 11\",\"pages\":\"4-5\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-03-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alcoholism & Drug Abuse Weekly\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/adaw.34448\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alcoholism & Drug Abuse Weekly","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/adaw.34448","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Industry considers concerns about masking in MDMA trials
Not for the first time, experts have expressed concern about whether randomized controlled trials (RCTs) can be conducted with psychedelics. A placebo for a drug with such a powerful effect would be difficult to create. But placebos are needed to prove that a medication works because it works, not because the patient thinks it will (the so-called “placebo effect”). To avoid the placebo effect misguiding results, participants are “blinded” as to whether they are taking the placebo or the study drug. (In “double-blind” studies, the researchers don't know, either.)